Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations

NCT03608371 is registered in ClinicalTrials.gov with BlackThorn Therapeutics, Inc. as lead sponsor.

NCT NCT03608371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03608371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations
Lead sponsor
BlackThorn Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2018
Completion date
April 23, 2019
Enrollment
24 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

motor disorder, parkinson disease